| Bioactivity | SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor Ki=7.49; μ-Opioid receptor Ki=2.70). SR-16435 can relieve pain[1]. |
| In Vivo | SR 16435 (10, 30 mg/kg; s.c.; single-dose) produces dose-dependent increase in tail-flick latency and induces antinociception[1].SR 16435 (10, 30 mg/kg; s.c. once daily for 9 days) produces an increase in tail-lick latency across days, induces conditioned place preference, and decreases global activity[1]. Animal Model: |
| Name | SR-16435 |
| CAS | 857262-16-9 |
| Formula | C22H30N2O |
| Molar Mass | 338.49 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Khroyan TV, et al. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice. J Pharmacol Exp Ther. 2007;320(2):934-943. |
SR-16435
CAS: 857262-16-9 F: C22H30N2O W: 338.49
SR-16435 is a nociceptin/orphanin FQ (NOP)/μ-opioid receptor partial agonist, with high binding affinity (NOP receptor
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.